Waterstone Pharmaceuticals, Inc.

Waterstone Pharmaceuticals, Inc. is dedicated to the research and development of pharmaceutical products aimed at treating metabolic diseases such as diabetic kidney disease, hyperuricemia, and gout, enhancing patient health outcomes. Founded in 2008 in Carmel, US, Waterstone Pharmaceuticals, Inc. focuses on developing pharmaceutical solutions for metabolic diseases.

The company has executed 2 deals, with the most recent deal occurring on September 26, 2012, when they raised USD 19 mn in VENTURE DEBT funding. Faming Zhang is the founder of the company. Waterstone Pharmaceuticals specializes in the research, development, and production of pharmaceutical products targeting metabolic diseases, particularly diabetic kidney disease, hyperuricemia, and gout. The company produces high molecular polymer intermediates, active pharmaceutical ingredients (APIs), and advanced formulations, utilizing proprietary platforms for drug and medical material selection.

Their offerings aim to alleviate chronic health conditions, focusing on enhancing the quality of life for patients, and their target customers include healthcare providers, hospitals, and pharmacies across various international markets. Waterstone Pharmaceuticals' revenue model is primarily based on B2B transactions, partnering with healthcare institutions and distributing through pharmaceutical wholesalers. The company engages in direct sales of its key products, supported by services like regulatory consultation, product training, and after-sales support. Revenue is generated through bulk purchases and contractual agreements, fostering long-term relationships with clients to ensure a consistent revenue flow through repeat business within the healthcare sector.

Waterstone Pharmaceuticals plans to leverage the recent VENTURE DEBT funding of USD 19 mn from September 2012 to enhance its product development initiatives and expand its market reach. The company is focusing on launching new products targeting additional metabolic disease segments and aims to enter new international markets. Specific regions targeted for expansion include Europe and Asia, with plans to establish a presence by 2024.